Kamada (KMDA) Cost of Revenue (2012 - 2026)
Kamada (KMDA) posted quarterly Cost of Revenue of $26.1 million for Q1 2026, up 12.27% year-on-year from $23.3 million in Q1 2025, and down 5.73% on a QoQ basis from $27.7 million in Q4 2025.
Kamada (KMDA) Cost of Revenue (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cost of Revenue for 15 consecutive years, with $26.1 million the latest figure, recorded in Q1 2026.
- Quarterly Cost of Revenue rose 12.27% year-over-year to $26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 billion (up 9.81% YoY) and the FY2025 annual result came in at $104.1 million, up 14.36% from the prior year.
- Cost of Revenue fell to $26.1 million in Q1 2026 per KMDA's latest filing, from $27.7 million in the prior quarter.
- Over the last five years, Cost of Revenue for KMDA reached as high as $25.8 billion in Q2 2025 and fell as low as $16.3 million in Q2 2022.
- A 5-year average of $5.2 billion and a median of $24.5 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue surged 112287.59% — and 2024, when it sank 99.89%.
- Year by year, Cost of Revenue stood at $30.1 million in 2022, then fell by 26.96% to $22.0 million in 2023, then slipped by 0.21% to $22.0 million in 2024, then climbed by 26.11% to $27.7 million in 2025, then fell by 5.73% to $26.1 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $26.1 million, $27.7 million, and $27.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Kamada | 399.49 Mn | 326.34 Mn | 19.12 Mn | 26.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.12 Mn |
| Mar 31, 2026 | 26.12 Mn |
| Dec 31, 2025 | 27.71 Mn |
| Dec 31, 2025 | 27.71 Mn |
| Sep 30, 2025 | 27.25 Mn |
| Sep 30, 2025 | 27.25 Mn |
| Jun 30, 2025 | 25.83 Bn |
| Jun 30, 2025 | 25.83 Bn |
| Mar 31, 2025 | 23.27 Mn |
| Mar 31, 2025 | 23.27 Mn |
| Dec 31, 2024 | 21.97 Mn |
| Dec 31, 2024 | 21.97 Mn |
| Sep 30, 2024 | 24.51 Mn |
| Sep 30, 2024 | 24.51 Mn |
| Jun 30, 2024 | 23.52 Bn |
| Jun 30, 2024 | 23.52 Bn |
| Mar 31, 2024 | 20.99 Mn |
| Mar 31, 2024 | 20.99 Mn |
| Dec 31, 2023 | 22.02 Mn |
| Dec 31, 2023 | 22.02 Mn |